challenge new drug discovery tuberculosis 
tuberculosis tb prevalent world today time human history mycobacterium tuberculosis pathogen responsible tb uses diverse strategies survive variety host lesions evade immune surveillance key question robust approaches discovering new tb drugs measures taken reduce long protracted clinical development new drugs emergence multi-drug-resistant strains m tuberculosis makes discovery new molecular scaffolds priority current situation even necessitates re-engineering repositioning old drug families achieve effective control whatever strategy used success will depend largely proper understanding complex interactions pathogen human host review discuss innovations tb drug discovery evolving strategies bring newer agents quickly patients 
